Kairos Pharma (NYSEAMERICAN:KAPA) Stock to Reverse Split on Tuesday, September 1st

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) shares are going to reverse split on Tuesday, September 1st. The 1-7 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, August 31st.

Kairos Pharma Price Performance

NYSEAMERICAN KAPA traded down $0.06 on Monday, hitting $0.23. The stock had a trading volume of 1,701,340 shares, compared to its average volume of 660,022. The business’s fifty day moving average price is $0.35 and its 200 day moving average price is $0.49. Kairos Pharma has a 52-week low of $0.22 and a 52-week high of $2.11.

Kairos Pharma (NYSEAMERICAN:KAPA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.06) EPS for the quarter. Analysts forecast that Kairos Pharma will post -0.37 EPS for the current fiscal year.

Institutional Trading of Kairos Pharma

An institutional investor recently raised its position in Kairos Pharma stock. XTX Topco Ltd boosted its stake in shares of Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) by 290.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 48,494 shares of the company’s stock after purchasing an additional 36,086 shares during the period. XTX Topco Ltd owned approximately 0.23% of Kairos Pharma worth $34,000 at the end of the most recent reporting period.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.